WASHINGTON--The list of genomics companies planning initial public offerings continues to grow, with Paradigm Genetics, Nanogen, and Sangamo Biosciences about to join the fray. All three have filed IPO registration statements with the Securities and Exchange Commission.
Paradigm is industrializing the process of gene function determination for four major sectors: crop production, nutrition, human health, and industrial products. Nanogen integrates microelectronics and molecular biology into a technology platform with commercial applications in genomics and related industries and possibly electronics and telecommunications. Sangamo develops novel transcription factors for gene expression regulation.
Other companies in the genomics and bioinformatics industry that have been rumored to be on the verge of making offerings on US stock exchanges include Compugen of Tel Aviv, Israel; DeCode Genetics of Reykjavik, Iceland; Exelixis of South San Francisco, Calif.; Lexicon Genetics of the Woodlands, Texas; Lion Bioscience of Heidelberg, Germany; NetGenics of Cleveland; and Physiome Sciences of Princeton, NJ, a developer of computer-based models of organs for use in drug discovery.